The role of diffusion 3-Tesla MRI in detecting prostate cancer before needle biopsy: Multiparametric study of 111 patients;Rôle de l'IRM de diffusion pour la détection du cancer de la prostate avant ponction biopsie : Étude multiparamétrique de 111 patients à 3 Tesla

Journal de Radiologie

Volumn 91, Issue 11 C1, 2010, Pages 1121-1128

  Roy, C ^a   Pasquali, R ^a   Matau, A ^a   Bazille, G ^a   Lang, H ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Cancer of the prostate; Diffusion imaging; MRI

Indexed keywords

GADOLINIUM; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION COEFFICIENT; ECHO PLANAR IMAGING; HUMAN; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; ULTRASOUND;

EID: 79251563185     PISSN: 02210363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0221-0363(10)70157-8     Document Type: Article

References (35)

1. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004;172:1297-301.
2. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology 2007;245:28-53.
3. Heijmink SW, Futterer JJ, Hambrock T, Huisman HJ. A comparison of the diagnostic performance of systematic versus ultrasound-guided biopsies of prostate cancer. Eur Radiol 2006;16:927-38.
4. Kirkham AP, Emberton M, Allen C. How good is MRI at detecting and characterising cancer within the prostate? Eur Urol 2006;50:1163-74.
5. Ikonen S, Karkkainen P, Kivisaari L, Salo JO, Taari K, Vehmas T et al. Prostatic MR imaging. Accuracy in differentiating cancer from other prostatic disorders. Acta Radiol 2001;42:348-544.
6. Lemaitre L, Rouvière O, Penna-Renard R, Villers A, Puech P. L'IRM du cancer de la prostate: un changement de paradigme. J Radiol 2008;89:1053-64.
7. Heijmink SW, Futterer JJ, Hambrock T, Takahashi S, Scheenen TW, Huisman HJ. Prostate cancer: body-array versus endorectal coil MR imaging at 3 T-comparison of image quality, localization, and staging performance. Radiology 2007;244:184-95.
8. Kim CK, Byung K, Kim B. Localization of prostate cancer using 3T MRI: comparison of T2-weighted and dynamic contrastenhanced imaging. J Comp Assist Tomog 2006;30:7-11.
9. Schlemmer HP, Merkle J, Grobholz R. Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? Eur Radiol 2004;14:309-17.
10. Jager, Ruijter ET, van de Kaa CA, et al. Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. Radiology 1997;203:645-52.
11. Villers A, Leroy X, Biserte J, Fantoni JC, Lemaitre L. Dynamic contrast-enhanced MRI for preoperative identification of localised prostate cancer. Eur Urol 2007;6:525-32.
12. Ben Cheikh AB, Girouin N, Colombel M, et al. Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before reat biopsy. Eur Radiol 2009;19:770-8.
13. Girouin N, Mege-Lechevallier F, Tonina Senes A, et al. Prostate dynamic contrastenhanced MRI with simple visual diagnostic criteria: is it reasonable? Eur Radiol 2007;17:1498-509.
14. Kozlowski P, Chang, Goldenberg SL. Diffusion-weighted MRI in prostate cancer - comparison between single-shot fast spin echo and echo planar imaging sequences. Magn Reson Imaging 2008;26:72-6.
15. Norris DG. The effects of microscopic tissue parameters on the diffusion weighted magnetic resonance imaging experiment. NMR Biomed 2001;14:77-93.
16. Mazaheri Y, Dave AS, Hricak H, et al. Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging - correlation with pathologic findings. Radiology 2008;246:480-8.
17. Miao H, Fukatsu H, Ishigaki T. Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging. Eur J Radiol 2007;61:297-302.
18. Noworolski SM, Henry RG, Vigneron DB, Kurhanewicz J. Dynamic contrast-enhanced MRI and MR diffusion imaging to distinguish between glandular and stromal prostatic tissues. Magn Reson Imaging 2008;26:1071-80.
19. Tamada T, Sone T, Tosshimitsu S, Imai S, Jo Y, Yoshida K. Age-related and zonal anatomical changes of apparent diffusion coefficient values in normal human prostatic tissues. J Magn Reson Imaging 2008;27:552-6.
20. Yoshimitsu K, Kiyoshima K, Irie H, Tajima T, Asayama Y, et al. Usefulness of apparent diffusion coefficient map in diagnosing prostate carcinoma: correlation with stepwise histopathology. J Magn Reson Imaging 2008;27:132-9.
21. van As NJ, de Souza NM, Riches SF, Morgan VA, et al. A Study of diffusionweighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. Eur Radiol 2008;56:981-8.
22. Kumar V, Jagannathan NR, Kumar R, Thulkar S, Gupta SD, Dwivedi SN. Correlation between metabolite ratios and ADC values of prostate in men with increased PSA level. Magn Reson Imaging 2006;24:541-8.
23. Shimofusa R, Shimofusa R, Fujimoto H, Akamata H. Diffusion-weighted imaging of prostate cancer. J Comput Assist Tomogr 2005;29:149-53.
24. de Souza NM, Reinsberg SA, Scurr ED, Brewster JM, Payne GS. Magnetic resonance imaging in prostate cancer: the value of apparent diffusion coefficients for identifying malignant nodules. Br J Radiol 2007;80:90-5.
25. Kim CK, Park B K, Kim B. Value of diffusion-weighted imaging for the prediction of prostate cancer location at 3T using a phased-array coil: preliminary results. Invest Radiol 2007;42:842-7.
26. Kozlowski P, Chang SD, Jones EC, Berean KW, Chen H, Goldenberg SL. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis correlation with biopsy and histopathology. J Magn Reson Imaging 2006;24:108-13.
27. Sato C, Naganawa S, Nakamura T, et al. Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging 2005;21:258-62.
28. 2. AJR 2010;194:W33-W37.
29. Lim HK, Kim JK, Kim KA, Cho KS. Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection - a multireader study. Radiology 2009;250:145-51.
30. Haider MA, van der Kwast TH, Tanguay J, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. Am J Roentgenol 2007;189:32.
31. Guichard G, Larré S, Gallina A, et al. Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. Eur Urol 2007;52:430-5.
32. Mitterberger M, Pinggera GM, Horninger W et al. Comparison of contrast enhanced color Doppler targeted biopsy to conventional systematic biopsy: impact on Gleason score. J Urol 2007;178:464-8.
33. Park BK, Lee HM, Kim CK, Choi HY, Park JW. Lesion localization in patients with a previous negative transrectal ultrasound biopsy and persistently elevated prostate specific antigen level using diffusion-weighted imaging at three Tesla before rebiopsy. Invest Radiol 2008;43:789-93.
34. Lawrentschuk N, Fleshner N. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels. BJU Int 2009;103:730-3.
35. Shimizu T, Nishie A, Ro T, Tajima T, et al. Prostate Cancer Detection: The Value of Performing an MRI before a Biopsy. Acta Radiol 2009;50:1080-8.